tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cue Biopharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Dev Prasad initiated coverage of Cue Biopharma (CUE) with a Buy rating and $4 price target The company’s lead asset CUE-401 is a novel bispecific for autoimmune disease, the analyst tells investors in a research note. The firm believes preclinical data show “strong mechanistic validation and broad efficacy” across autoimmune models.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1